The market performance of CRISPR Therapeutics AG’s stock has been harmonious in recent times. Over the last year, the company’s stock reached its highest point at $91.10 on 02/22/24, while the lowest value for the same duration was $39.76 on 09/06/24.
52-week price history of CRSP Stock
Studying a stock’s 52-week price history, which includes both low and high prices, can help gauge its current status and potential future performance. CRISPR Therapeutics AG’s current trading price is -45.75% away from its 52-week high, while its distance from the 52-week low is 24.30%. The stock’s price range during the 52-week period has remained between $39.76 and $91.10. In the Healthcare sector, the company’s shares saw a trading volume of around 0.85 million for the day, which was evidently lower than the average daily volume of 1.11 million over the past three months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Market Capitalization and Financial Performance: An In-Depth Look
CRISPR Therapeutics AG (CRSP) has experienced a quarterly decline of -0.48% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 4.21B and boasts a workforce of 407 employees.
Making Sense of Trading Volume and Moving Average Data
Based on Barchart.com data, the company’s moving average over the 100-day period was 50.91, with a change in price of -13.56. Similarly, CRISPR Therapeutics AG recorded 1,193,115 in trading volume during the last 100 days, posting a change of -21.77%.
Examining CRSP’s Debt-to-Equity Ratio: What You Need to Know
The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for CRSP stands at 0.12. Similarly, the long-term debt-to-equity ratio is also 0.11.
CRSP Stock Stochastic Average
CRISPR Therapeutics AG’s raw stochastic average for the past 50 days is presently 62.17%, as of today. This marks a decrease from the raw stochastic average of the last 20 days, which was 71.09%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 53.62% and 60.41%, respectively.
CRSP Stock Price Performance Analysis
Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. This year’s metric has recorded a Price decrease of -21.05%. However, over the past six months, we’ve seen a stronger performance of -11.58%. The price of CRSP fallen by 10.07% over the last 30 days. And in the last five days, it has surged by 4.35%.
